Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Jespersen

Showing results (31-40 of 269) with videos related to

Pageof 27
Sort By:
The American Journal of Medicine|June 24, 1991
Increased fibrinolytic potential induced by gliclazide in types I and II diabetic patientsJ Gram, J Jespersen
Lancet (London, England)|November 2, 1985
Chronic interstitial cystitis and subcutaneous heparinJ Jespersen, T Astrup
Clinical Chemistry|October 1, 1985
Improved assay of antithrombin-III. Effects of certain additives on thrombin and on chromogenic peptide substratesJ Gram, J Jespersen
Lancet (London, England)|August 27, 1994
alpha-Linolenic acid and reduction of cardiac deathsP Marckmann, J Jespersen
Haemostasis|January 1, 1983
A study of the fibrin plate assay of fibrinolytic agents. Optimal conditions, reproducibility and precisionJ Jespersen, T Astrup
Thrombosis and Haemostasis|August 30, 1985
On the significance of antithrombin-III, alpha 2-macroglobulin, alpha 2-antiplasmin, histidine-rich glycoprotein, and protein C in patients with acute myocardial infarction and deep vein thrombosisJ Gram, J Jespersen
Clinical Nephrology|November 1, 1981
Lowering of the dosage of intravenous heparin hemodialysis by priming with subcutaneous heparinJ Jespersen, G Gregersen
Thrombosis and Haemostasis|December 27, 1982
Decreased levels of histidine-rich glycoprotein (HRG) and increased levels of free plasminogen in women on oral contraceptives low in estrogenJ Jespersen, C Kluft
Ugeskrift for Laeger|June 30, 1986
[Protein C deficiency and thrombosis. Physiological and clinical aspects]J Gram, J Jespersen
Thrombosis and Haemostasis|April 7, 1987
A selective depression of tissue plasminogen activator (t-PA) activity in euglobulins characterises a risk group among survivors of acute myocardial infarctionJ Gram, J Jespersen
Pageof 27

Showing results (31-40 of 269) with videos related to

Sort By:
Pageof 27
The American Journal of Medicine|June 24, 1991
Increased fibrinolytic potential induced by gliclazide in types I and II diabetic patientsJ Gram, J Jespersen
Lancet (London, England)|November 2, 1985
Chronic interstitial cystitis and subcutaneous heparinJ Jespersen, T Astrup
Clinical Chemistry|October 1, 1985
Improved assay of antithrombin-III. Effects of certain additives on thrombin and on chromogenic peptide substratesJ Gram, J Jespersen
Lancet (London, England)|August 27, 1994
alpha-Linolenic acid and reduction of cardiac deathsP Marckmann, J Jespersen
Haemostasis|January 1, 1983
A study of the fibrin plate assay of fibrinolytic agents. Optimal conditions, reproducibility and precisionJ Jespersen, T Astrup
Thrombosis and Haemostasis|August 30, 1985
On the significance of antithrombin-III, alpha 2-macroglobulin, alpha 2-antiplasmin, histidine-rich glycoprotein, and protein C in patients with acute myocardial infarction and deep vein thrombosisJ Gram, J Jespersen
Clinical Nephrology|November 1, 1981
Lowering of the dosage of intravenous heparin hemodialysis by priming with subcutaneous heparinJ Jespersen, G Gregersen
Thrombosis and Haemostasis|December 27, 1982
Decreased levels of histidine-rich glycoprotein (HRG) and increased levels of free plasminogen in women on oral contraceptives low in estrogenJ Jespersen, C Kluft
Ugeskrift for Laeger|June 30, 1986
[Protein C deficiency and thrombosis. Physiological and clinical aspects]J Gram, J Jespersen
Thrombosis and Haemostasis|April 7, 1987
A selective depression of tissue plasminogen activator (t-PA) activity in euglobulins characterises a risk group among survivors of acute myocardial infarctionJ Gram, J Jespersen
Pageof 27